Advertisement
News
Advertisement

Chimerix to Present at Cowen and Company 31st Annual Health Care Conference

Tue, 03/01/2011 - 4:36am
Bio-Medicine.Org

DURHAM, N.C., March 1, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present at the Cowen and Company 31st Annual Health Care Conference on March 8, 2011, 1:30 pm ET, at the Boston Marriott Copley Place in Boston, Massachusetts. The Cowen and Company Health Care Conference is a conference for institutional investors focused on private and emerging public life science companies.

Mr. Moch will give an update on the company's pipeline and technology assets, including CMX001, a broad-spectrum antiviral being developed for the treatment of a wide range of infections caused by double-stranded DNA (dsDNA) viruses. CMX001 is in Phase 2 clinical studies in immunocompromised transplant and cancer patients for the prophylaxis and/or pre-emption of dsDNA viruses, including BK virus and adenovirus.  It is also undergoing an Open-Label study for the treatment of patients with any of 12 dsDNA infections which is designed to provide promising data for CMX001's fundamental studies.  In addition, CMX001 is being developed as a potential countermeasure in the event of a smallpox release.

About Chimerix and CMX001

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.

The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA (dsDNA) viral diseases. Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans.

Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant p

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading